{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:43:20Z","timestamp":1788227000215,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24wm0625512h"],"award-info":[{"award-number":["JP24wm0625512h"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25wm0625512h"],"award-info":[{"award-number":["JP25wm0625512h"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12149-025-02095-8","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T16:12:34Z","timestamp":1755015154000},"page":"1319-1325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Feasibility of targeted alpha therapy for Alzheimer\u2019s disease using 211At-labeled agent targeting amyloid-\u03b2 aggregates"],"prefix":"10.1007","volume":"39","author":[{"given":"Rikuto","family":"Kashiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Ooe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2497-039X","authenticated-orcid":false,"given":"Masahiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"2095_CR1","doi-asserted-by":"crossref","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2024;20(5):3708\u2013821.","DOI":"10.1002\/alz.13809"},{"key":"2095_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fninf.2021.630172","volume":"15","author":"L Stefanovski","year":"2021","unstructured":"Stefanovski L, Meier JM, Pai RK, Triebkorn P, Lett T, Martin L, et al. Bridging scales in Alzheimer\u2019s disease: biological framework for brain simulation with the virtual brain. Front Neuroinform. 2021;15: 630172.","journal-title":"Front Neuroinform"},{"issue":"2","key":"2095_CR3","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"Collaborators GBDDF","year":"2022","unstructured":"Collaborators GBDDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105\u201325.","journal-title":"Lancet Public Health"},{"issue":"9","key":"2095_CR4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"GF Chen","year":"2017","unstructured":"Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. Amyloid-\u03b2: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38(9):1205\u201335.","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"2095_CR5","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry. 2021;26(10):5481\u2013503.","journal-title":"Mol Psychiatry"},{"issue":"5054","key":"2095_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184\u20135.","journal-title":"Science"},{"issue":"9","key":"2095_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698\u2013712.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2095_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. BioDrugs. 2024;38(1):5\u201322.","journal-title":"BioDrugs"},{"issue":"18","key":"2095_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"1","key":"2095_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"34","key":"2095_CR11","doi-asserted-by":"publisher","first-page":"22752","DOI":"10.1021\/acsnano.4c06851","volume":"18","author":"J Lin","year":"2024","unstructured":"Lin J, Yu Z, Gao X. Advanced noninvasive strategies for the brain delivery of therapeutic proteins and peptides. ACS Nano. 2024;18(34):22752\u201379.","journal-title":"ACS Nano"},{"issue":"3","key":"2095_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13311-013-0187-4","volume":"10","author":"YJ Yu","year":"2013","unstructured":"Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. 2013;10(3):459\u201372.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"2095_CR13","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.14283\/jpad.2024.159","volume":"11","author":"LBE Shields","year":"2024","unstructured":"Shields LBE, Hust H, Cooley SD, Cooper GE, Hart RN, Dennis BC, et al. Initial experience with Lecanemab and lessons learned in 71 patients in a regional medical center. J Prev Alzheimers Dis. 2024;11(6):1549\u201362.","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"2095_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr., Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367\u201385.","journal-title":"Alzheimers Dement"},{"key":"2095_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.nucmedbio.2020.08.004","volume":"92","author":"JL Hatcher-Lamarre","year":"2021","unstructured":"Hatcher-Lamarre JL, Sanders VA, Rahman M, Cutler CS, Francesconi LC. Alpha emitting nuclides for targeted therapy. Nucl Med Biol. 2021;92:228\u201340.","journal-title":"Nucl Med Biol"},{"issue":"3","key":"2095_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","volume":"33","author":"YS Kim","year":"2012","unstructured":"Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol. 2012;33(3):573\u201390.","journal-title":"Tumour Biol"},{"issue":"5","key":"2095_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s44211-024-00514-w","volume":"40","author":"M Munekane","year":"2024","unstructured":"Munekane M, Fuchigami T, Ogawa K. Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics. Anal Sci. 2024;40(5):803\u201326.","journal-title":"Anal Sci"},{"issue":"7","key":"2095_CR18","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","volume":"18","author":"MR Gill","year":"2017","unstructured":"Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017;18(7):e414\u201323.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2095_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2967\/jnumed.124.267482","volume":"65","author":"AA Bender","year":"2024","unstructured":"Bender AA, Kirkeby EK, Cross DJ, Minoshima S, Roberts AG, Mastren TE. Development of a 213Bi-labeled pyridyl benzofuran for targeted alpha-therapy of amyloid-\u03b2 aggregates. J Nucl Med. 2024;65(9):1467\u201372.","journal-title":"J Nucl Med"},{"key":"2095_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2022.110555","volume":"191","author":"EK Kirkeby","year":"2023","unstructured":"Kirkeby EK, Chyan MK, Diehl G, Wilbur DS, Li Y, Roberts AG, et al. Design and synthesis of astatinated benzothiazole compounds for their potential use in targeted alpha therapy (TAT) strategies to treat Alzheimer\u2019s disease-associated amyloid plaques. Appl Radiat Isot. 2023;191: 110555.","journal-title":"Appl Radiat Isot"},{"issue":"4","key":"2095_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd.2015.21","volume":"15","author":"WA Banks","year":"2016","unstructured":"Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15(4):275\u201392.","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"2095_CR22","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1016\/j.bmcl.2010.08.016","volume":"20","author":"Y Cheng","year":"2010","unstructured":"Cheng Y, Ono M, Kimura H, Kagawa S, Nishii R, Saji H. A novel 18F-labeled pyridyl benzofuran derivative for imaging of \u03b2-amyloid plaques in Alzheimer\u2019s brains. Bioorg Med Chem Lett. 2010;20(20):6141\u20134.","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"2095_CR23","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1021\/jm200057u","volume":"54","author":"M Ono","year":"2011","unstructured":"Ono M, Cheng Y, Kimura H, Cui M, Kagawa S, Nishii R, et al. Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of \u03b2-amyloid plaques in Alzheimer\u2019s brains. J Med Chem. 2011;54(8):2971\u20133879.","journal-title":"J Med Chem"},{"issue":"9","key":"2095_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074104","volume":"8","author":"M Ono","year":"2013","unstructured":"Ono M, Cheng Y, Kimura H, Watanabe H, Matsumura K, Yoshimura M, et al. Development of novel 123I-labeled pyridyl benzofuran derivatives for SPECT imaging of \u03b2-amyloid plaques in Alzheimer\u2019s disease. PLoS ONE. 2013;8(9): e74104.","journal-title":"PLoS ONE"},{"issue":"1","key":"2095_CR25","first-page":"1","volume":"28","author":"F Guerard","year":"2013","unstructured":"Guerard F, Gestin JF, Brechbiel MW. Production of [211At]-astatinated radiopharmaceuticals and applications in targeted alpha-particle therapy. Cancer Biother Radiopharm. 2013;28(1):1\u201320.","journal-title":"Cancer Biother Radiopharm"},{"key":"2095_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.nucmedbio.2021.05.007","volume":"100\u2013101","author":"Y Feng","year":"2021","unstructured":"Feng Y, Zalutsky MR. Production, purification and availability of 211At: near term steps towards global access. Nucl Med Biol. 2021;100\u2013101:12\u201323.","journal-title":"Nucl Med Biol"},{"issue":"6","key":"2095_CR27","first-page":"425","volume":"35","author":"S Lindegren","year":"2020","unstructured":"Lindegren S, Albertsson P, Back T, Jensen H, Palm S, Aneheim E. Realizing clinical trials with astatine-211: the chemistry infrastructure. Cancer Biother Radiopharm. 2020;35(6):425\u201336.","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"2095_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/cbic.200800765","volume":"10","author":"A Taniguchi","year":"2009","unstructured":"Taniguchi A, Sohma Y, Hirayama Y, Mukai H, Kimura T, Hayashi Y, et al. \u201cClick peptide\u201d: pH-triggered in situ production and aggregation of monomer A\u03b21-42. ChemBioChem. 2009;10(4):710\u20135.","journal-title":"ChemBioChem"},{"issue":"31","key":"2095_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202405605","volume":"63","author":"H Umeda","year":"2024","unstructured":"Umeda H, Suda K, Yokogawa D, Azumaya Y, Kitada N, Maki SA, et al. Unimolecular chemiexcited oxygenation of pathogenic amyloids. Angew Chem Int Ed. 2024;63(31): e202405605.","journal-title":"Angew Chem Int Ed"},{"issue":"11","key":"2095_CR30","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/pro.5560041120","volume":"4","author":"CN Pace","year":"1995","unstructured":"Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 1995;4(11):2411\u201323.","journal-title":"Protein Sci"},{"key":"2095_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116357","volume":"46","author":"R Yudi Utomo","year":"2021","unstructured":"Yudi Utomo R, Asawa Y, Okada S, Ban HS, Yoshimori A, Bajorath J, et al. Development of curcumin-based amyloid-\u03b2 aggregation inhibitors for Alzheimer\u2019s disease using the SAR matrix approach. Bioorg Med Chem. 2021;46: 116357.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"2095_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13568-021-01333-2","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Cui G, Cui Y, Chen D, Lin H. Small molecule targeting amyloid fibrils inhibits Streptococcus mutans biofilm formation. AMB Express. 2021;11(1):171.","journal-title":"AMB Express"},{"key":"2095_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0076-6879(99)09020-5","volume":"309","author":"H LeVine 3rd","year":"1999","unstructured":"LeVine H 3rd. Quantification of \u03b2-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274\u201384.","journal-title":"Methods Enzymol"},{"issue":"2","key":"2095_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/0003-2697(89)90046-8","volume":"177","author":"H Naiki","year":"1989","unstructured":"Naiki H, Higuchi K, Hosokawa M, Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal Biochem. 1989;177(2):244\u20139.","journal-title":"Anal Biochem"},{"issue":"1","key":"2095_CR35","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.160696","volume":"4","author":"C Xue","year":"2017","unstructured":"Xue C, Lin TY, Chang D, Guo Z. Thioflavin t as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R Soc Open Sci. 2017;4(1): 160696.","journal-title":"R Soc Open Sci"},{"issue":"5959","key":"2095_CR36","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1126\/science.1178250","volume":"326","author":"TP Knowles","year":"2009","unstructured":"Knowles TP, Waudby CA, Devlin GL, Cohen SI, Aguzzi A, Vendruscolo M, et al. An analytical solution to the kinetics of breakable filament assembly. Science. 2009;326(5959):1533\u20137.","journal-title":"Science"},{"key":"2095_CR37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0076-6879(99)09022-9","volume":"309","author":"H Naiki","year":"1999","unstructured":"Naiki H, Gejyo F. Kinetic analysis of amyloid fibril formation. Methods Enzymol. 1999;309:305\u201318.","journal-title":"Methods Enzymol"},{"issue":"5","key":"2095_CR38","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1046\/j.1471-4159.1998.70051781.x","volume":"70","author":"WM Pardridge","year":"1998","unstructured":"Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 1998;70(5):1781\u201392.","journal-title":"J Neurochem"},{"issue":"11","key":"2095_CR39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11910-014-0500-6","volume":"14","author":"N Okamura","year":"2014","unstructured":"Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer\u2019s disease. Curr Neurol Neurosci Rep. 2014;14(11):500.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"2095_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0969-8051(97)00230-8","volume":"25","author":"RH Larsen","year":"1998","unstructured":"Larsen RH, Slade S, Zalutsky MR. Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds. Nucl Med Biol. 1998;25(4):351\u20137.","journal-title":"Nucl Med Biol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02095-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02095-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02095-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:04:32Z","timestamp":1762808672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02095-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2095"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02095-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2025-6qdbr","asserted-by":"object"}]},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}